Quick Answer
Marker Therapeutics, Inc. reported Research And Development Expense of $11.80 million for the year ending 2025.
- Marker Therapeutics, Inc. showed a decrease of -12.4% in Research And Development Expense from 2024 to 2025.
- This data is from Marker Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Marker Therapeutics, Inc.'s Research And Development Expense has grown by 3,968.0%.
- Historical annual values: Fiscal year 2025: $11.80 million | Fiscal year 2024: $13.47 million | Fiscal year 2023: $10.42 million | Fiscal year 2022: $11.97 million | Fiscal year 2021: $27.79 million | Fiscal year 2020: $18.88 million | Fiscal year 2019: $12.76 million | Fiscal year 2018: $7.95 million | Fiscal year 2017: $5.25 million | Fiscal year 2016: $3.80 million | Fiscal year 2015: $1.71 million | Fiscal year 2014: $189.0 thousand | Fiscal year 2013: $697.6 thousand | Fiscal year 2012: $1.06 million | Fiscal year 2011: $203.7 thousand | Fiscal year 2010: $290.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: